BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 22789543)

  • 21. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
    Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
    Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
    Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
    Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
    Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
    Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
    Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
    Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
    Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
    Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
    Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
    Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
    Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
    Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
    EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.
    Higashi M; Sakai K; Fumino S; Aoi S; Furukawa T; Tajiri T
    Surg Today; 2019 Sep; 49(9):721-727. PubMed ID: 30848386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
    Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
    Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
    Epstein LF; Chen H; Emkey R; Whittington DA
    J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
    Yi B; Yang J; Wang L
    Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
    Schönherr C; Ruuth K; Yamazaki Y; Eriksson T; Christensen J; Palmer RH; Hallberg B
    Biochem J; 2011 Dec; 440(3):405-13. PubMed ID: 21838707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
    Barone G; Anderson J; Pearson AD; Petrie K; Chesler L
    Clin Cancer Res; 2013 Nov; 19(21):5814-21. PubMed ID: 23965898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
    Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
    Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALK positively regulates MYCN activity through repression of HBP1 expression.
    Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
    Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.